Requirement for early donor cell chimerism during prolonged survival of murine skin allografts.
BACKGROUND
Posttransplantation infusion of donor bone marrow cells (BMC) can prolong allograft survival in antilymphocyte antibody- (ALA) treated recipients. This study examined the hypothesis that chimerism of donor BMC origin contributes to allograft unresponsiveness.


METHODS
Survival of day 0 skin grafts from C3H (H2k) donors was prolonged on ALA-treated B6AF1 mice by day +7 infusion of BMC from C3H or C3H-H2o2 (H2K(d)I(d)D(k)) mice. To test for functional chimerism, depletional anti-H2Kd antibody was injected at intervals after C3H-H2o2 BMC infusion. To confirm the persistence of active cells in the recipients, cells harvested from bone marrow of ALA- and C3H BMC-treated primary recipients were transferred to secondary ALA-treated recipients. Other recipients were infused on day +21 with additional donor BMC or light-density BMC that had been cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) to promote the differentiation of dendritic cells (DC).


RESULTS
Injection of depletional antibody targeting infused BMC interrupted skin graft survival, whether the injection was made on day +7, 2 hr after BMC injection, or as late as day +28. Prolonged graft survival was transferred to secondary recipients with cells recovered from primary recipient marrow as long as 4 weeks after initial donor BMC treatment. Graft survival prolonged by day +7 BMC was further enhanced by infusion on day +21 of light density cultured BMC, although a second dose of unfractionated BMC was inactive. Repeated injection of cultured BMC at 2-week intervals after day +21 prolonged graft survival even further.


CONCLUSIONS
These data directly demonstrate that at least short-term donor BMC-derived microchimerism is required for prolonged allograft survival. The data further suggest that the active chimeric cells persist in recipient marrow. Finally, the beneficial effect of late infusion of cultured cells containing partially differentiated DC suggest that DC may be the active chimeric cells.
Masli
S
S
Bouvé College of Pharmacy and Health Sciences, Northeastern University, Boston, Massachusetts 02115, USA.
De Fazio
S R
SR
Gozzo
J J
JJ
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000276:immunology; D016026:Bone Marrow Transplantation; D002678:Chimera / Q000502:physiology*; D003713:Dendritic Cells / Q000637:transplantation; D006085:Graft Survival / Q000502:physiology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D016038:Skin Transplantation; D033581:Stem Cell Transplantation; D013997:Time Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous
D000906:Antibodies